Prescriber's Corner

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma

Nancy M. Nix, PharmD, BCPS, BCOP, and Kirk Braun*

From St. Joseph’s/Candler Health System, South Carolina Cancer Specialists, Hilton Head, South Carolina; University of Georgia College of Pharmacy, Athens, Georgia

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Correspondence to: Nancy M. Nix, PharmD, BCPS, BCOP, South Carolina Cancer Specialists, PO Box 21824, Hilton Head, SC 29925. E-mail: nixna@sjchs.org


J Adv Pract Oncol 2014;5:47-50# | DOI: 10.6004/jadpro.2014.5.1.10 | © 2014 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.